KPRX
Kiora Pharmaceuticals, Inc.
There isn't enough reported data to score KPRX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
KPRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
KPRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KPRX PE Valuation
KPRX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
KPRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect KPRX's losses to shrink, with revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | -$0.53 |
| Q2 2026 | -$2.50 | +$0.58 |
| Q1 2026 | -$2.70 | +$0.37 |
| Q4 2025 | -$2.64 | -403% |
| Q3 2022 | -$367.47 | +$183.33 |
| Q2 2022 | -$417.60 | +$187.20 |
| Q1 2022 | -$478.80 | +$136.80 |
| Q4 2021 | -$514.80 | +$122.40 |
KPRX lost $2.79 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over KPRX on earnings quality, reporting a profit while its opponent remains loss making.
KPRX Quarterly Revenue
KPRX's revenue is growing: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -169% | N/A |
| Q2 2024 | -12724% | N/A |
| Q1 2024 | 83% | N/A |
OSCR has the edge over KPRX on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over KPRX on profitability, with a higher operating margin.
KPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$557.9K | +$715.6K |
| Q1 2026 | -$3.2M | -$462.2K |
| Q4 2025 | -$2.3M | -$51.3K |
| Q3 2025 | -$1.3M | -238% |
| Q1 2025 | -$2.7M | -120% |
| Q4 2024 | -$2.2M | +$374K |
| Q3 2024 | $920.1K | +$3.4M |
| Q1 2024 | $13.6M | +$16.7M |
KPRX has burned cash in almost every quarter: −$8M over the past year, against −$5M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
KPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +117K shares |
| 1 year | +44% | +1.9M shares |
| 3 years | +2940% | +6.1M shares |
| 5 years | +49822% | +6.3M shares |
KPRX has 6M diluted shares, up 44% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over KPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | -12.0x | Net Cash |
KPRX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
KPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.6 | Oversold |
| Stochastic | 1.2 | Oversold |
KPRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KPRX PE vs Healthcare Sector
KPRX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 36% below |
| 20 week MA | $2.40 | 45% below |
| 50 week MA | $2.31 | 42% below |
| 100 week MA | $2.64 | 50% below |
| 200 week MA | $6.48 | 79% below |
KPRX is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over KPRX on trend strength, trading above more of its moving averages.
KPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,351.6 | $2,138.4 | -36% |
| 2021 | $2,138.4 | $312.5 | -85% |
| 2022 | $312.5 | $22.1 | -93% |
| 2023 | $22.1 | $4.70 | -79% |
| 2024 | $4.70 | $3.29 | -30% |
| 2025 | $3.29 | $1.97 | -40% |
| 2026 YTD | $1.97 | $1.33 | -32% |
KPRX has finished every year since 2020 lower, and it's down 32% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KPRX on returns for 2026, with the stronger performance.